177 related articles for article (PubMed ID: 1558834)
1. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.
Mills DC; Puri R; Hu CJ; Minniti C; Grana G; Freedman MD; Colman RF; Colman RW
Arterioscler Thromb; 1992 Apr; 12(4):430-6. PubMed ID: 1558834
[TBL] [Abstract][Full Text] [Related]
2. Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.
Savi P; Laplace MC; Maffrand JP; Herbert JM
J Pharmacol Exp Ther; 1994 May; 269(2):772-7. PubMed ID: 8182545
[TBL] [Abstract][Full Text] [Related]
3. Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate is mediated by its binding to a putative ADP receptor, aggregin.
Puri RN; Colman RF; Colman RW
Eur J Biochem; 1996 Mar; 236(3):862-70. PubMed ID: 8665907
[TBL] [Abstract][Full Text] [Related]
4. Two mechanisms for inhibition of ADP-induced platelet shape change by 5'-p-fluorosulfonylbenzoyladenosine. Conversion to adenosine, and covalent modification at an ADP binding site distinct from that which inhibits adenylate cyclase.
Mills DC; Figures WR; Scearce LM; Stewart GJ; Colman RF; Colman RW
J Biol Chem; 1985 Jul; 260(13):8078-83. PubMed ID: 2989276
[TBL] [Abstract][Full Text] [Related]
5. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.
Gachet C; Cattaneo M; Ohlmann P; Hechler B; Lecchi A; Chevalier J; Cassel D; Mannucci PM; Cazenave JP
Br J Haematol; 1995 Oct; 91(2):434-44. PubMed ID: 8547091
[TBL] [Abstract][Full Text] [Related]
6. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain.
Puri RN; Zhou FX; Bradford H; Hu CJ; Colman RF; Colman RW
Arch Biochem Biophys; 1989 Jun; 271(2):346-58. PubMed ID: 2543293
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8-(4-bromo-2,3-dioxobutylthio)ADP.
Puri RN; Kumar A; Chen H; Colman RF; Colman RW
J Biol Chem; 1995 Oct; 270(41):24482-8. PubMed ID: 7592664
[TBL] [Abstract][Full Text] [Related]
8. Aggregin: a platelet ADP receptor that mediates activation.
Colman RW
FASEB J; 1990 Mar; 4(5):1425-35. PubMed ID: 2407587
[TBL] [Abstract][Full Text] [Related]
9. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
10. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits.
Defreyn G; Gachet C; Savi P; Driot F; Cazenave JP; Maffrand JP
Thromb Haemost; 1991 Feb; 65(2):186-90. PubMed ID: 2053105
[TBL] [Abstract][Full Text] [Related]
11. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man.
Gachet C; Stierlé A; Cazenave JP; Ohlmann P; Lanza F; Bouloux C; Maffrand JP
Biochem Pharmacol; 1990 Jul; 40(2):229-38. PubMed ID: 2375765
[TBL] [Abstract][Full Text] [Related]
12. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel.
Hechler B; Eckly A; Ohlmann P; Cazenave JP; Gachet C
Br J Haematol; 1998 Dec; 103(3):858-66. PubMed ID: 9858246
[TBL] [Abstract][Full Text] [Related]
13. Effect of clopidogrel treatment on ADP-induced phosphorylations in rat platelets.
Savi P; Artçanuthurry V; Bornia J; Grelac F; Maclouf J; Levy-Toledano S; Herbert JM
Br J Haematol; 1997 Apr; 97(1):185-91. PubMed ID: 9136964
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of an ADP receptor mediating platelet activation.
Colman RW; Figures WR
Mol Cell Biochem; 1984; 59(1-2):101-11. PubMed ID: 6323960
[TBL] [Abstract][Full Text] [Related]
15. Characterization of P2x1 purinoreceptors on rat platelets: effect of clopidogrel.
Savi P; Bornia J; Salel V; Delfaud M; Herbert JM
Br J Haematol; 1997 Sep; 98(4):880-6. PubMed ID: 9326183
[TBL] [Abstract][Full Text] [Related]
16. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
17. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1.
Gachet C; Cazenave JP; Ohlmann P; Bouloux C; Defreyn G; Driot F; Maffrand JP
Biochem Pharmacol; 1990 Dec; 40(12):2683-7. PubMed ID: 2175608
[TBL] [Abstract][Full Text] [Related]
18. Evidence for the existence of two different ADP-binding sites on rat platelets.
Savi P; Laplace MC; Herbert JM
Thromb Res; 1994 Oct; 76(2):157-69. PubMed ID: 7863466
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ADP-induced platelet shape change and aggregation by o-phthalaldehyde: evidence for covalent modification of cysteine and lysine residues.
Puri RN; Colman RW
Arch Biochem Biophys; 1991 May; 286(2):419-27. PubMed ID: 1910292
[TBL] [Abstract][Full Text] [Related]
20. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes--an effect selectively blocked by the thienopyridine clopidogrel.
Gachet C; Savi P; Ohlmann P; Maffrand JP; Jakobs KH; Cazenave JP
Thromb Haemost; 1992 Jul; 68(1):79-83. PubMed ID: 1514178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
